NEW YORK — MRC Holland said on Thursday that its blood-based assay for Temple, Kagami-Ogata, and Russell-Silver syndromes has received certification under Europe's In Vitro Diagnostic Regulation (IVDR ...
The company said that its molecular diagnostics revenues rose 7 percent on the strength of its women's health assays and Biotheranostics business.
Total revenues were $3.33 billion, up from $3.03 billion in the same quarter last year and slightly above the consensus Wall Street estimate of $3.31 billion.
The company said that growth in its diagnostics business was partly offset by declines in the Americas and China.
The company said that its molecular diagnostics revenues rose 7 percent on the strength of its women's health assays and Biotheranostics business.
一些您可能无法访问的结果已被隐去。
显示无法访问的结果